

## Fabry Disease

Resource	Address
Agency for Healthcare Research and Quality (AHRQ). Primary Care Practice Facilitation Curriculum. Module 24: Introduction to the Care Model. 2015;15-0060-EF.	<a href="https://www.ahrq.gov/sites/default/files/wysiwyg/ncepcr/tools/PCMH/pcpf-module-24-care-model.pdf">https://www.ahrq.gov/sites/default/files/wysiwyg/ncepcr/tools/PCMH/pcpf-module-24-care-model.pdf</a>
Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: A multicenter study. <i>J Am Soc Nephrol</i> . 2017;28:1631-1641.	<a href="https://pubmed.ncbi.nlm.nih.gov/27979989/">https://pubmed.ncbi.nlm.nih.gov/27979989/</a>
Arends M, Wijburg FA, Wanner C, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. <i>Mol Genet Metab</i> . 2017;121:157-161.	<a href="https://pubmed.ncbi.nlm.nih.gov/28495078/">https://pubmed.ncbi.nlm.nih.gov/28495078/</a>
Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. <i>Mol Genet Metab Rep</i> . 2021;28:100786.	<a href="https://pubmed.ncbi.nlm.nih.gov/34401344/">https://pubmed.ncbi.nlm.nih.gov/34401344/</a>
Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. <i>Orphanet J Rare Dis</i> . 2015;10:36.	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383065/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383065/</a>
Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the chronic care model in the new millennium. <i>Health Aff (Millwood)</i> . 2009;2:75-85.	<a href="https://pubmed.ncbi.nlm.nih.gov/19124857/">https://pubmed.ncbi.nlm.nih.gov/19124857/</a>
Del Pino M, Andrés A, Bernabéu AÁ, et al. Fabry nephropathy: An evidence-based narrative review. <i>Kidney Blood Press Res</i> . 2018;43:406-421.	<a href="https://pubmed.ncbi.nlm.nih.gov/29558749/">https://pubmed.ncbi.nlm.nih.gov/29558749/</a>
Dommm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. <i>Mol Genet Metab</i> . 2021;134:117-131.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S1096719221007575">https://www.sciencedirect.com/science/article/abs/pii/S1096719221007575</a>
Eikrem Ø, Skrunes R, Tøndel C, et al. Pathomechanisms of renal Fabry disease. <i>Cell Tissue Res</i> . 2017;369:53-62.	<a href="https://pubmed.ncbi.nlm.nih.gov/28401309/">https://pubmed.ncbi.nlm.nih.gov/28401309/</a>
Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. <i>J Inher Metab Dis</i> . 2007;30:184-192.	<a href="https://pubmed.ncbi.nlm.nih.gov/17347915/">https://pubmed.ncbi.nlm.nih.gov/17347915/</a>
Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: An overview. In: Mehta A, Beck M, Sunder-Plassmann G, eds. <i>Fabry Disease: Perspectives from 5 Years of FOS</i> . Oxford: Oxford PharmaGenesis; 2006. Chapter 2.	<a href="https://www.ncbi.nlm.nih.gov/books/NBK11603/">https://www.ncbi.nlm.nih.gov/books/NBK11603/</a>
Galafold™ (migalastat). Prescribing Information. Amicus Therapeutics, Inc; 2018.	<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208623lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208623lbl.pdf</a>
Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: Previously unrecognized manifestations of Fabry disease. <i>Clin Genet</i> . 2005;68:93-95.	<a href="https://pubmed.ncbi.nlm.nih.gov/15952993/">https://pubmed.ncbi.nlm.nih.gov/15952993/</a>

<p>Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. <i>N Engl J Med</i>. 2016;375:545-555.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27509102/">https://pubmed.ncbi.nlm.nih.gov/27509102/</a></p>
<p>Hongo K. Cardiac involvement in Fabry disease - A non-invasive assessment and the role of specific therapies. <i>Mol Genet Metab</i>. 2022;137:179-186.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/36088815/">https://pubmed.ncbi.nlm.nih.gov/36088815/</a></p>
<p>Hopkin RJ, Cabrera G, Charrow J, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. <i>Mol Genet Metab</i>. 2016;119:151-159.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27510433/">https://pubmed.ncbi.nlm.nih.gov/27510433/</a></p>
<p>Hopkin RJ, Ganash J, Deegan P, et al. STAAR, a phase 1/2 study of isargalgene civaparvovec (ST-920) gene therapy in adults with Fabry disease. Presented at: 19th Annual <i>WORLDSymposium</i>; February 22-26, 2023. Orlando, FL.</p>	<p><a href="https://www.neurologylive.com/view/gene-therapy-st-920-shows-favorable-impact-fabry-disease-phase-1-2-study">https://www.neurologylive.com/view/gene-therapy-st-920-shows-favorable-impact-fabry-disease-phase-1-2-study</a></p>
<p>Hopkin RJ, Jefferies JL, Laney DA, et al. The management and treatment of children with Fabry disease: A United States-based perspective. <i>Mol Genet Metab</i>. 2016;117:104-113.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/26546059/">https://pubmed.ncbi.nlm.nih.gov/26546059/</a></p>
<p>Hsu TR, Hung SC, Chang FP, et al. Later onset Fabry disease, cardiac damage progress in silence: Experience with a highly prevalent mutation. <i>J Am Coll Cardiol</i>. 2016;68:2554-2563.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27931613/">https://pubmed.ncbi.nlm.nih.gov/27931613/</a></p>
<p>Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. <i>J Med Genet</i>. 2023;60:722-731.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/36543533/">https://pubmed.ncbi.nlm.nih.gov/36543533/</a></p>
<p>Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>J Med Genet</i>. 2017;54:288-296.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/27834756/">https://pubmed.ncbi.nlm.nih.gov/27834756/</a></p>
<p>Kistler AD, Altintis MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. <i>Kidney Int</i>. 2012;81:1053-1055.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/22584591/">https://pubmed.ncbi.nlm.nih.gov/22584591/</a></p>
<p>Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry disease: Molecular basis, pathophysiology, diagnostics and potential therapeutic directions. <i>Biomolecules</i>. 2021;11:271.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/33673160/">https://pubmed.ncbi.nlm.nih.gov/33673160/</a></p>
<p>Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: Recommendations of the National Society of Genetic Counselors. <i>J Genet Couns</i>. 2013;22:555-564.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/23860966/">https://pubmed.ncbi.nlm.nih.gov/23860966/</a></p>
<p>Laney DA, Peck DS, Atherton AM, et al. Fabry disease in infancy and early childhood: A systematic literature review. <i>Genet Med</i>. 2015;17:323-330.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/25232851/">https://pubmed.ncbi.nlm.nih.gov/25232851/</a></p>
<p>Lipinski SE, Komlodi-Pasztor E, Goker-Alpan O. Agalsidase alfa for the treatment of fabry disease: A closer look. <i>Clin invest</i>. 2014;4:567-584.</p>	<p><a href="https://www.openaccessjournals.com/articles/agalsidase-alfa-for-the-treatment-of-fabry-disease-a-closer-look.pdf">https://www.openaccessjournals.com/articles/agalsidase-alfa-for-the-treatment-of-fabry-disease-a-closer-look.pdf</a></p>

McDonald KM, Sundaram V, Bravata DM, et al. Closing the quality gap: A critical analysis of quality improvement strategies, Volume 7—Care Coordination. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; June 2007.	<a href="https://www.ncbi.nlm.nih.gov/books/NBK44015/">https://www.ncbi.nlm.nih.gov/books/NBK44015/</a>
Mehta A, Hughes DA. Fabry disease. 2002 Aug 5 [Updated 2023 Mar 9]. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023.	<a href="https://www.ncbi.nlm.nih.gov/books/NBK1292/">https://www.ncbi.nlm.nih.gov/books/NBK1292/</a>
Mehta AB, Orteu CH. Chapter 127: Fabry disease. In: Kang S, Amagai M, Bruckner AL, et al, eds. <i>Fitzpatrick's Dermatology</i> . 9th ed. McGraw Hill; 2019.	<a href="https://accessmedicine.mhmedical.com/content.aspx?sectionid=210437902&amp;bookid=2570">https://accessmedicine.mhmedical.com/content.aspx?sectionid=210437902&amp;bookid=2570</a>
Mersebach H, Johansson JO, Rasmussen AK, et al. Osteopenia: A common aspect of Fabry disease. Predictors of bone mineral density. <i>Genet Med</i> . 2007;9:812-818.	<a href="https://pubmed.ncbi.nlm.nih.gov/18091430/">https://pubmed.ncbi.nlm.nih.gov/18091430/</a>
Michaud M, Mauhin W, Belmatoug N, et al. When and how to diagnose Fabry disease in clinical practice. <i>Am J Med Sci</i> . 2020;360:641-649.	<a href="https://pubmed.ncbi.nlm.nih.gov/32723516/">https://pubmed.ncbi.nlm.nih.gov/32723516/</a>
National Institutes of Health (NIH). National Center for Advancing Translational Sciences (NCATS). Multidisciplinary machine-assisted, genomic analysis and clinical approaches to shortening the rare diseases diagnostic odyssey. Last updated January 26, 2023.	<a href="https://ncats.nih.gov/programs/diagnostic-odyssey">https://ncats.nih.gov/programs/diagnostic-odyssey</a>
Nowak A, Mechtler TP, Hornemann T, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. <i>Mol Genet Metab</i> . 2018;123:148-153.	<a href="https://pubmed.ncbi.nlm.nih.gov/28728877/">https://pubmed.ncbi.nlm.nih.gov/28728877/</a>
Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. <i>Mol Genet Metab</i> . 2018;123:416-427.	<a href="https://pubmed.ncbi.nlm.nih.gov/29530533/">https://pubmed.ncbi.nlm.nih.gov/29530533/</a>
Ortolano S. Small molecules: Substrate inhibitors, chaperones, stop-codon read through, and beyond. <i>J Inborn Errors Metab Screen</i> . 2016;4:1-11.	<a href="https://journals.sagepub.com/doi/full/10.1177/2326409816666297">https://journals.sagepub.com/doi/full/10.1177/2326409816666297</a>
Putko BN, Wen K, Thompson RB, et al. Anderson-Fabry cardiomyopathy: Prevalence, pathophysiology, diagnosis and treatment. <i>Heart Fail Rev</i> . 2015;20:179-191.	<a href="https://pubmed.ncbi.nlm.nih.gov/25030479/">https://pubmed.ncbi.nlm.nih.gov/25030479/</a>
Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. <i>Int J Clin Pract</i> . 2017;71:e12914.	<a href="https://pubmed.ncbi.nlm.nih.gov/28097762/">https://pubmed.ncbi.nlm.nih.gov/28097762/</a>
Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. <i>Mol Genet Metab</i> . 2017;122:19-27.	<a href="https://pubmed.ncbi.nlm.nih.gov/28947349/">https://pubmed.ncbi.nlm.nih.gov/28947349/</a>
Seydelmann N, Wanner C, Störk S, Ertl G, Weidemann F. Fabry disease and the heart. <i>Best Pract Res Clin Endocrinol Metab</i> . 2015;29:195-204.	<a href="https://pubmed.ncbi.nlm.nih.gov/25987173/">https://pubmed.ncbi.nlm.nih.gov/25987173/</a>

<p>Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. <i>J Med Genet.</i> 2015;52:262-268.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/25596309/">https://pubmed.ncbi.nlm.nih.gov/25596309/</a></p>
<p>Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. <i>Am J Hum Genet.</i> 2006;79:31-40.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/16773563/">https://pubmed.ncbi.nlm.nih.gov/16773563/</a></p>
<p>Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. <i>J Am Soc Nephrol.</i> 2013;24:137-148.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/23274955/">https://pubmed.ncbi.nlm.nih.gov/23274955/</a></p>
<p>van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. <i>Biochim Biophys Acta.</i> 2011;1812:70-76.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/20851180/">https://pubmed.ncbi.nlm.nih.gov/20851180/</a></p>
<p>Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. <i>Genet Med.</i> 2007;9:34-45.</p>	<p><a href="https://pubmed.ncbi.nlm.nih.gov/17224688/">https://pubmed.ncbi.nlm.nih.gov/17224688/</a></p>
<p>Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone therapy in Fabry disease. <i>Int J Mol Sci.</i> 2022;23:1887.</p>	<p><a href="https://www.mdpi.com/1422-0067/23/3/1887">https://www.mdpi.com/1422-0067/23/3/1887</a></p>

All URLs accessed August 23, 2023